Randomized, Double Blind Evaluation of Late Boost Strategies With IHV01 (FLSC in Aluminum Phosphate) and A244 With or Without ALFQ for HIV-uninfected Participants in the HIV Vaccine Trial RV306 / WRAIR 1920
Latest Information Update: 20 Jun 2023
Price :
$35 *
At a glance
- Drugs HIV vaccine (Primary) ; Monophosphoryl lipid A; QS 21
- Indications HIV infections
- Focus Adverse reactions
- 15 Jun 2023 Planned End Date changed from 1 Mar 2027 to 1 May 2027.
- 15 Jun 2023 Planned primary completion date changed from 1 Mar 2023 to 30 May 2024.
- 15 Feb 2022 Planned End Date changed from 1 Oct 2026 to 1 Mar 2027.